Prometheus Phase II Data For Novel TL1A Inhibitor Impresses On Efficacy

 
• By Jessica Merrill

The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.

Bullseye
Prometheus hit the mark on a key Phase II trial • Source: Shutterstock

More from Clinical Trials

More from R&D